3 Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks With a Strong Future Roadmap: Aurobindo Pharma, Indo Borax & Chemicals and ITC
- October 19, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Aurobindo Pharma Rs 1,666.90, P/E 25.46. Indo Borax Rs 472.40, P/E 27.49. ITC Rs 263.50, P/E 15.77. Closing prices of 14 Oct 2026.
Quick Answer
Formulation exporter, borax producer and diversified FMCG group stocks with the clearest long-term roadmaps today include Aurobindo Pharma in generic formulations and active ingredients sold in the US, Europe and emerging markets, Indo Borax in boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and ITC in cigarettes, packaged foods, personal care, paperboards, hotels and agri products. FY26 revenue growth was 5.6% at Aurobindo Pharma, 21.0% at Indo Borax and 4.4% at ITC. P/E stands at 25.46 for Aurobindo Pharma (industry 37.59), 27.49 for Indo Borax (industry 36.60) and 15.77 for ITC (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Formulation exporter, borax producer and diversified FMCG group stocks give investors exposure to medicines, industrial chemicals and consumer goods sold across markets. Volumes, export demand and margins decide how much of that demand turns into profit.
Readers comparing formulation exporter, borax producer and diversified FMCG group stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.
This list covers three formulation exporter, borax producer and diversified FMCG group stocks: Aurobindo Pharma for generic formulations and active ingredients sold in the US, Europe and emerging markets, Indo Borax & Chemicals for boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and ITC for cigarettes, packaged foods, personal care, paperboards, hotels and agri products. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks?
Formulation exporter, borax producer and diversified FMCG group stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three formulation exporter, borax producer and diversified FMCG group stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,666.90 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
| Indo Borax & Chemicals | 472.40 | 1,548 | 27.49 | 36.60 | 11.09% | 0.00 |
| ITC | 263.50 | 318,338 | 15.77 | 34.85 | 28.53% | 0.03 |
Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.
Why Do Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks Have a Strong Roadmap in India?
Formulation exporter, borax producer and diversified FMCG group stocks have a strong roadmap in India because generic drug demand overseas, glass and farm chemical use and wider consumer brand reach keep adding volumes for these firms. Three drivers stand out.
- Generic demand: Overseas markets buy affordable formulations and ingredients.
- Boron use: Glass, ceramics and farms consume boron chemicals.
- Brand spread: Packaged foods and personal care reach more homes.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
Indo Borax & Chemicals: Boron Chemicals Anchor the Roadmap
Indo Borax’s roadmap rests on boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture, with wide industrial usage supporting volumes.
Revenue grew from Rs 178.93 crore in FY22 to Rs 230.89 crore in FY26, a 29.0% rise, and FY26 revenue was 21.0% higher than FY25. FY26 net profit rose 18.3% to Rs 50.27 crore. Over four years, net profit rose from Rs 36.37 crore in FY22 to Rs 50.27 crore. In Q1 FY27, revenue grew 28.9% to Rs 72.92 crore, and net profit rose 59.3% to Rs 16.25 crore. Operating margin was 27.28% in FY26 and 31.78% in Q1 FY27 against 28.43% a year earlier.
Debt to equity is 0.00 and return on equity is 11.09%. FY26 operating cash flow was Rs 87.15 crore against capital expenditure of Rs 0.29 crore. Indo Borax paid a dividend of Rs 1 per share for FY26, a yield of 0.21%. At a P/E of 27.49 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 31.78% against 27.28% for FY26, so margin stability is the figure to follow as volumes grow.
ITC: Several Businesses Anchor the Roadmap
ITC’s roadmap rests on cigarettes, packaged foods, personal care, paperboards, hotels and agri products, with several businesses supporting steady cash flow.
Revenue grew from Rs 62,504.44 crore in FY22 to Rs 81,294.27 crore in FY26, a 30.1% rise, and FY26 revenue was 4.4% higher than FY25. FY26 net profit rose 4.9% to Rs 21,018.15 crore. Over four years, net profit rose from Rs 15,503.13 crore in FY22 to Rs 21,018.15 crore. In Q1 FY27, revenue grew 26.7% to Rs 30,179.01 crore. Operating margin was 33.18% in FY26.
Debt to equity is 0.03 and return on equity is 28.53%. FY26 operating cash flow was Rs 18,464.31 crore against capital expenditure of Rs 2,182.89 crore. At a P/E of 15.77 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: The P/E of 15.77 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks in India: Aurobindo Pharma vs Indo Borax vs ITC on Key Financials
Among the best formulation exporter, borax producer and diversified FMCG group stocks in India, Aurobindo Pharma ranks second on FY26 revenue growth and the lowest P/E; Indo Borax leads on FY26 revenue growth and Q1 FY27 revenue growth; ITC leads on FY26 operating margin and return on equity. The table puts the numbers side by side.
| Metric | Aurobindo Pharma | Indo Borax | ITC |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 34,145.17 | 230.89 | 81,294.27 |
| FY26 revenue growth | 5.6% | 21.0% | 4.4% |
| FY26 net profit (Rs Cr) | 3,502.97 | 50.27 | 21,018.15 |
| FY26 net profit growth | 0.6% | 18.3% | 4.9% |
| FY26 operating profit margin | 21.61% | 27.28% | 33.18% |
| Q1 FY27 revenue growth (YoY) | 18.1% | 28.9% | 26.7% |
| Return on equity | 9.25% | 11.09% | 28.53% |
| P/E ratio | 25.46 | 27.49 | 15.77 |
| Debt to equity | 0.21 | 0.00 | 0.03 |
| FY26 operating cash flow (Rs Cr) | 5,526.37 | 87.15 | 18,464.31 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen formulation exporter, borax producer and diversified FMCG group stocks and shortlist formulation exporter, borax producer and diversified FMCG group stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma, Indo Borax and ITC live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover generics, boron chemicals and a consumer conglomerate. Aurobindo Pharma ranks second on FY26 revenue growth and the lowest P/E; Indo Borax leads on FY26 revenue growth and Q1 FY27 revenue growth; ITC leads on FY26 operating margin and return on equity.
Across formulation exporter, borax producer and diversified FMCG group stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the formulation exporter, borax producer and diversified FMCG group stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Formulation Exporter, Borax Producer and Diversified FMCG Group Stocks
Which are the best formulation exporter, borax producer and diversified FMCG group stocks in India with a strong roadmap?
Ans. Aurobindo Pharma, Indo Borax & Chemicals and ITC stand out for their roadmaps in generics, boron chemicals and a consumer conglomerate. FY26 revenue growth was 5.6% at Aurobindo Pharma, 21.0% at Indo Borax and 4.4% at ITC, and return on equity ranges from 9.25% to 28.53%.
Is Aurobindo Pharma a good stock to buy now?
Ans. Aurobindo Pharma has a debt to equity ratio of 0.21, a return on equity of 9.25% and a P/E of 25.46 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Aurobindo Pharma, Indo Borax and ITC?
Ans. The P/E ratio is 25.46 for Aurobindo Pharma (industry 37.59), 27.49 for Indo Borax (industry 36.60) and 15.77 for ITC (industry 34.85). All of them trade below the industry multiple.
Which of these formulation exporter, borax producer and diversified FMCG group stocks has the highest return on equity?
Ans. ITC has the highest return on equity at 28.53%, followed by Indo Borax & Chemicals at 11.09% and Aurobindo Pharma at 9.25%.
What are the risks of investing in formulation exporter, borax producer and diversified FMCG group stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Aurobindo Pharma, Indo Borax and ITC perform in Q1 FY27?
Ans. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. Indo Borax & Chemicals reported revenue of Rs 72.92 crore, up 28.9% year on year, and net profit rose 59.3% to Rs 16.25 crore. ITC reported revenue of Rs 30,179.01 crore, up 26.7% year on year.
Do formulation exporter, borax producer and diversified FMCG group stocks pay dividends?
Ans. Aurobindo Pharma and Indo Borax pay dividends. The dividend yield is 0.25% for Aurobindo Pharma and 0.21% for Indo Borax, based on dividends declared for FY26.
How can I invest in formulation exporter, borax producer and diversified FMCG group stocks in India?
Ans. You can buy formulation exporter, borax producer and diversified FMCG group stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
